Nihon Medi-physics Company, Limited

Chiba University

Kagoshima University

Kaken Co., Ltd.

Bio Med Core Incorporation

Yasushi Arano

Akira Yokoyama

Tomoya Uehara

Hiroyuki Suzuki

Masahiro Murakami

Yuji Ito

Akira Yamada

Katsuyoshi Tatenuma

Yoshinari Shoyama

Yu Ogawa

Emi Kaneko

Hisashi Tanaka

Tadashi Hatano

Yasuhiro Magata

Koji Ishikawa

Atsushi Tanaka

Takeo Hosotani

Tsuneyuki Noguchi

Tomomi Ueda

Kiyoko Kurosawa

Shota Komoto

Described is a labeling technique which can facilitate the metabolism in the liver after administration to patients without the reduction in the antibody function, thereby reducing accumulation of radionuclides in an organ such as the liver, and a modified antibody containing an IgG antibody and an IgG-binding peptide bound to the IgG antibody. The IgG-binding peptide has an amino acid sequence consisting of 13 to 17 amino acid residues, such as GPDCAYH(Xaa1)GELVWCTFH (SEQ ID NO: 2) wherein Xaa1 represents a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, 2-aminosuberic acid, or diaminopropionic acid, and a compound represented by the following formula (II-1) is linked at a position of the lysine residue via a modification linker to the N terminus of the IgG-binding peptide.

Modified antibody and radioactive metal-labelled antibody

Described are: [1] a compound or the like represented by the formula (1); [2] a compound or the like having a target molecule recognition element bound to the compound or the like described in the above [1]; and [3] a metal complex compound or the like having a metal selected from the group consisting of a radioactive metal and a radioactive atom-labeled metal, and the compound or the like described in the above [1] or [2] coordinated to the metal. Also described are uses of the compound or the like described in the above [1] or [2] or the metal complex compound or the like described in the above [3] in a radioactive drug, a radiotherapeutic agent or a radioactive diagnostic imaging agent. 

Metal complex forming compound, metal complex compound formed thereof, radioactive drug containing the metal complex compound, and method of using and preparing the metal complex compound

Described are: [1] a compound represented by the formula (1), [2] a compound containing the compound according to [1] and a target molecule recognition element bonded thereto, [3] a metal complex compound containing one kind of a metal selected from a radioactive metal and a radioactive atom-labeled metal, and the compound according to [1] or [2], which is coordinated to the metal, [4] a drug for preparing a radiolabeled drug, containing the compound according to [1] or [2], [5] use of the compound according to [1] or [2], for producing a radiolabeled drug, [6] a radiolabeled drug containing the metal complex compound according to [3], and [7] a radiodiagnostic imaging agent containing the metal complex compound according to [3]: 

Radiolabeled drug

To useTc as a raw material for a radioactive medicine, a very small amount ofTc in the high concentration Mo(Mo) solution is purified and recovered with high yield without contamination ofMo.Tc with high purity is recovered by forming a high concentration Mo(Mo) solution which contains radionuclidesMo which is the parent nuclide ofTc used for the radioactive medicine and the raw material for its labeled compound, forming a high concentration Mo(Mo) solution which contains radionuclidesMo andTc by generatingTc to a radioactive-equilibrium state, gettingTc in the high concentration Mo(Mo) solution adsorbed to activated carbon selectively by feeding the solution to an adsorption column which has activated carbon, and undergoing desorption and purification treatment ofTc with a desorbent from the activated carbon to whichTc is adsorbed.

Method of recovering enriched radioactive technetium and system therefor

An object of the present invention is to provide a method of producing liposome wherein a complex of a short half-life metallic radioactive nuclide such asTc and CD is encapsulated, with radiochemical yield and purity enabling practical application. The present invention provides a method of producing a liposome wherein a complex of a short half-life metallic radioactive nuclide and ethylenedicysteine (CD) is encapsulated, which comprises mixing a complex of a short half-life metallic radioactive nuclide and N-[2-(1H-pyrrolylmethyl)]-N'-(4-penten-3-on-2)-ethane-1,2-diamine with an ethylenedicysteine (CD)-encapsulated liposome, and incubating the mixture.

Method of encapsulating metal complex within liposomes

A Tc-99m mononuclide complex compound of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are each a hydrogen atom or a C.sub.1 -C.sub.3 alkyl group and X is an anion, which is useful as a radioactive diagnostic agent for imaging of brain, cardiac muscle, pancreas or the like.

Tc-99m mononuclide complex compound

A radioactive diagnostic agent which comprises a physiologically active substance and a radioactive metallic element combined with a compound of the formula: ##STR1## wherein R is a hydrogen atom or a C.sub.1 -C.sub.3 alkyl group and n is an integer of 0 to 4. The agent is characteristic in having a high stability even after being administered into a human body and showing the substantially the same behavior as the physiologically active substance itself in a human body.

P-Glyoxyloylphenylalkanoic acid bis(thiosemicarbazone) derivatives, and

A radioactive diagnostic agent which comprises a physiologically active substance and a radioactive metallic element combined with a compound of the formula: ##STR1## wherein R, R', R.sup.1 and R.sup.2 are each a hydrogen atom or a C.sub.1 -C.sub.3 alkyl group and n is an integer of 0 to 3. The agent is characteristic in having a high stability even after being administered into a human body and showing the substantially the same behavior as the physiologically active substance itself in a human body.

1-(p-Substituted or unsubstituted aminoalkyl)phenylpropane-1,2-dione

A radioactive diagnostic agent for imaging of various organs, particularly of brain, which comprises a radioactive element such as .sup.99m TC and a non-radioactive carrier comprising as the essential component glucosone-bis(thiosemecarbazone) of the formula: ##STR1##

Radioactive diagnostic agent and its preparation

A radioactive diagnostic agent which comprises a protein and a radioactive metallic element combined with intervention of a bifunctional chelating agent of the formula: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each a hydrogen atom or a C.sub.1 -C.sub.3 alkyl group and is characteristic in having high stability even after administered into a human body.

Growing community of inventors

Chiba, Japan

Yasushi Arano